|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 333 Twin Dolphin Drive |
Address2 | Suite 600 |
City | Redwood City |
State | CA |
Zip Code | 94065 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401103810-12
|
||||||||
|
6. House ID# 430570001
|
TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: David Sanders |
Date | 1/21/2022 12:18:49 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Build Back Better Act
Drug Pricing
ASP+8 for biosimilars
Domestic Manufacturing
Medicare implications on biosimilars
Pass Through Status Extension
Appropriations and reach out pertaining to FDA inspections
HHS Supply Chain Readiness
HHS Biosimilar Uptake
340B Drug Pricing Program
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
H.R. 2815 - The BIOSIM Act
H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021
H.R. 2855 - Star Rating for Biosimilars
S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S. 1176 - Onshoring Essential Antibiotics Act
S. 1693 - Medical Supplies for Pandemics Act
340B Drug Pricing Program
HR 3683 Securing America's Pharmaceutical Supply Chain
S 2640 Disease X Act
S. 2662 Industrial Finance Corporation Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Natl Security Council (NSC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Sanders |
|
Legislative Affairs, Dept of Commerce, US Patent and Trademark Office (2005-2007)
Legislative Assistant, Representative Marsha Blackburn (2002-2004)
Legislative and Press Intern, Senator Fred Thompson (2000) |
|
Amanda |
Major |
|
|
|
Ben |
Kenney |
|
Director of Strategic Communications and Stakeholder Engagement, Centers for Medicare and Medicaid Services (2018-2021),
Associate Administrator, General Services Administration (2017-2018),
Legislative Aide, U.S. Sen. Daniel R. Coats (2011-2012) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code GOV
16. Specific lobbying issues
Repeal of Most Favored Nations Rule
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
OPPS Pass-Through Status Extension
Drug Pricing Reform
Biosimilars Policy
BARDA
ASPR Funding
17. House(s) of Congress and Federal agencies Check if None
White House Office, Health & Human Services - Dept of (HHS), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Sanders |
|
|
|
Amanda |
Major |
|
|
|
Benjamin |
Kenney |
|
CMS, HHS |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |